Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
-
Clin. Appl. Thromb. Hemost. · Nov 2011
Randomized Controlled Trial Multicenter StudyA randomized trial of aprotinin-free fibrin sealant versus absorbable hemostat.
This study evaluated the safety and hemostatic effectiveness of a tranexamic acid- and aprotinin-free fibrin sealant versus an absorbable hemostat in soft tissue during elective retroperitoneal or intra-abdominal surgery. ⋯ This tranexamic acid- and aprotinin-free fibrin sealant is safe and effective for achieving hemostasis in soft tissue during elective retroperitoneal or intra-abdominal surgery.
-
Clin. Appl. Thromb. Hemost. · Nov 2011
Multicenter StudyCongenital bleeding disorders in Karachi, Pakistan.
To determine the frequency of inherited bleeding disorders, its complications, and treatment modalities available for its treatment. ⋯ Hemophilia A and vWD are the most common congenital bleeding disorders in this study. Hemarthrosis involving knee joint was the most common complication. Inhibitor was detected in a significant number of patients. Plasma is still the most common modality of treatment.
-
Clin. Appl. Thromb. Hemost. · Nov 2011
The impact of age on the delay in diagnosis in patients with acute pulmonary embolism.
It has been speculated that the atypical clinical presentation of acute pulmonary embolism (PE) in older patients leads to a late diagnosis and therefore contributes to a worse prognosis. Therefore, we prospectively evaluated the delay in diagnosis and its relation to the in-hospital mortality in 202 patients with acute PE. ⋯ Older age was significantly associated with an increased risk for in-hospital mortality (OR 4.36, 95% CI 0.93-20.37, P = .043), whereas the delay in diagnosis was not associated with an increase of in-hospital mortality. We therefore conclude that the clinical presentation of acute PE in older patients cannot be considered as a risk factor for late diagnosis and is not responsible for their higher in-hospital death rate.
-
Clin. Appl. Thromb. Hemost. · Oct 2011
Multicenter Study Clinical TrialVenous thromboembolism risk and thromboprophylaxis among hospitalized patients: data from the Turkish arm of the ENDORSE study.
To evaluate venous thromboembolism (VTE) risk and use of thromboprophylaxis in the acute care hospital setting. ⋯ VTE remains a risk factor among patients hospitalized across Turkey, since identification as well as prophylaxis of patients at VTE risk seems to be neglected.
-
Clin. Appl. Thromb. Hemost. · Oct 2011
Clinical TrialAn evaluation of the DDAVP infusion test with PFA-100 and vWF activity assays to distinguish vWD types in children.
von Willebrand disease (vWD) is classified into partial (type 1), qualitative (type 2), and total deficiency (type 3). The aims of the study were to evaluate prospectively the potency of the DDAVP infusion test together with von Willebrand factor (vWF) ristocetin cofactor (vWF:RCo), vWF antigen (vWF:Ag), factor VIII coagulant activity (FVIII:C), and platelet function analyzer (PFA)-100 to distinguish vWD types. Genetic analysis and multimeric analysis of vWF was not applied. ⋯ The response to DDAVP of vWF parameters is normal in all patients with mild/moderate type 1 vWD, 6 patients with severe type 1 vWD or nonclassical type 2 vWD and 11 patients with type 2 vWD. In conclusion, this study showed that measurement of vWF:RCo, vWF:Ag, FVIII:C, and PFA-100 parameters can differentiate vWD types but not severe type 1 vWD or nonclassical type 2 vWD. In the differentiation of severe type 1 vWD and nonclassical type 2 vWD, DDAVP response may be used.